PNC Financial Services Group Inc. reduced its position in Organon & Co. (NYSE:OGN – Get Rating) by 3.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 242,004 shares of the company’s stock after selling 7,532 shares during the quarter. PNC Financial Services Group Inc. owned 0.10% of Organon & Co. worth $6,759,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently made changes to their positions in OGN. Vanguard Group Inc. raised its holdings in Organon & Co. by 1.8% in the third quarter. Vanguard Group Inc. now owns 30,230,471 shares of the company’s stock worth $707,394,000 after purchasing an additional 536,373 shares in the last quarter. Mawer Investment Management Ltd. raised its holdings in Organon & Co. by 22.1% in the fourth quarter. Mawer Investment Management Ltd. now owns 13,179,805 shares of the company’s stock worth $368,112,000 after purchasing an additional 2,381,668 shares in the last quarter. State Street Corp raised its holdings in Organon & Co. by 27.8% in the first quarter. State Street Corp now owns 11,958,385 shares of the company’s stock worth $417,706,000 after purchasing an additional 2,599,728 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Organon & Co. by 10.1% in the third quarter. Bank of New York Mellon Corp now owns 9,066,304 shares of the company’s stock worth $212,151,000 after purchasing an additional 834,392 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA raised its holdings in Organon & Co. by 0.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 7,575,257 shares of the company’s stock worth $177,260,000 after purchasing an additional 44,987 shares in the last quarter. 75.74% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Separately, Raymond James initiated coverage on shares of Organon & Co. in a report on Wednesday, March 15th. They issued an “outperform” rating and a $33.00 target price for the company.
Organon & Co. Stock Performance
Shares of OGN stock opened at $20.12 on Thursday. Organon & Co. has a fifty-two week low of $19.87 and a fifty-two week high of $39.09. The firm has a market capitalization of $5.13 billion, a price-to-earnings ratio of 6.89, a PEG ratio of 0.89 and a beta of 0.77. The stock’s 50-day simple moving average is $22.64 and its 200-day simple moving average is $25.62.
Organon & Co. (NYSE:OGN – Get Rating) last issued its earnings results on Thursday, May 4th. The company reported $1.08 EPS for the quarter, missing analysts’ consensus estimates of $1.18 by ($0.10). The firm had revenue of $1.54 billion during the quarter, compared to analysts’ expectations of $1.54 billion. Organon & Co. had a net margin of 12.14% and a negative return on equity of 119.00%. Organon & Co.’s quarterly revenue was down 1.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.65 EPS. As a group, equities analysts forecast that Organon & Co. will post 4.22 earnings per share for the current year.
Organon & Co. Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Thursday, June 15th. Investors of record on Monday, May 15th will be given a $0.28 dividend. The ex-dividend date is Friday, May 12th. This represents a $1.12 dividend on an annualized basis and a yield of 5.57%. Organon & Co.’s dividend payout ratio is currently 38.36%.
About Organon & Co.
(Get Rating)
Organon & Co, a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women’s health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Organon & Co., you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Organon & Co. wasn’t on the list.
While Organon & Co. currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Source: marketbeat.com
PNC Financial Services Group Inc. reduced its position in Organon & Co. (NYSE:OGN – Get Rating) by 3.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 242,004 shares of the company’s stock after selling 7,532 shares during the quarter. PNC Financial Services Group Inc. owned 0.10% of Organon & Co. worth $6,759,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently made changes to their positions in OGN. Vanguard Group Inc. raised its holdings in Organon & Co. by 1.8% in the third quarter. Vanguard Group Inc. now owns 30,230,471 shares of the company’s stock worth $707,394,000 after purchasing an additional 536,373 shares in the last quarter. Mawer Investment Management Ltd. raised its holdings in Organon & Co. by 22.1% in the fourth quarter. Mawer Investment Management Ltd. now owns 13,179,805 shares of the company’s stock worth $368,112,000 after purchasing an additional 2,381,668 shares in the last quarter. State Street Corp raised its holdings in Organon & Co. by 27.8% in the first quarter. State Street Corp now owns 11,958,385 shares of the company’s stock worth $417,706,000 after purchasing an additional 2,599,728 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Organon & Co. by 10.1% in the third quarter. Bank of New York Mellon Corp now owns 9,066,304 shares of the company’s stock worth $212,151,000 after purchasing an additional 834,392 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA raised its holdings in Organon & Co. by 0.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 7,575,257 shares of the company’s stock worth $177,260,000 after purchasing an additional 44,987 shares in the last quarter. 75.74% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Separately, Raymond James initiated coverage on shares of Organon & Co. in a report on Wednesday, March 15th. They issued an “outperform” rating and a $33.00 target price for the company.
Organon & Co. Stock Performance
Shares of OGN stock opened at $20.12 on Thursday. Organon & Co. has a fifty-two week low of $19.87 and a fifty-two week high of $39.09. The firm has a market capitalization of $5.13 billion, a price-to-earnings ratio of 6.89, a PEG ratio of 0.89 and a beta of 0.77. The stock’s 50-day simple moving average is $22.64 and its 200-day simple moving average is $25.62.
Organon & Co. (NYSE:OGN – Get Rating) last issued its earnings results on Thursday, May 4th. The company reported $1.08 EPS for the quarter, missing analysts’ consensus estimates of $1.18 by ($0.10). The firm had revenue of $1.54 billion during the quarter, compared to analysts’ expectations of $1.54 billion. Organon & Co. had a net margin of 12.14% and a negative return on equity of 119.00%. Organon & Co.’s quarterly revenue was down 1.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.65 EPS. As a group, equities analysts forecast that Organon & Co. will post 4.22 earnings per share for the current year.
Organon & Co. Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Thursday, June 15th. Investors of record on Monday, May 15th will be given a $0.28 dividend. The ex-dividend date is Friday, May 12th. This represents a $1.12 dividend on an annualized basis and a yield of 5.57%. Organon & Co.’s dividend payout ratio is currently 38.36%.
About Organon & Co.
(Get Rating)
Organon & Co, a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women’s health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Organon & Co., you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Organon & Co. wasn’t on the list.
While Organon & Co. currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Source: marketbeat.com
